| Taiho Oncology Europe GmbH - Lytgobi 4 mg, Filmtabletten | | 69714 | | 01 | | Lytgobi 4 mg | | Filmtabletten | | L01 | | ANTINEOPLASTISCHE MITTEL | | 08.10.2024 | | |
| | Composition | | futibatinibum 4 mg, natrii laurilsulfas corresp. natrium 0.3196 mg, lactosum monohydricum 5.4 mg, maydis amylum, hydroxypropylcellulosum, mannitolum 43.6 mg, cellulosum microcristallinum, crospovidonum, magnesii stearas, aqua purificata, Überzug: hypromellosum, macrogolum 6000, E 171, aqua purificata, magnesii stearas, pro compresso obducto. | | Packungsbestandteile | | Comprimés filmés | | | | | Principe actif | Concentr. |
|---|
| Futibatinibum | 4 mg |
| | BAG: Principe actif | Concentr. |
|---|
| Futibatinibum | 4 mg |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| Aqua Purificata | | | | Cellulosum Microcristallinum | | | | Crospovidonum | | | | E 171 | | color. | | Hydroxypropylcellulosum | | | | Hypromellosum | | Überzug | | Lactose Monohydrate | 5.4 mg | | | Macrogol | 6000 | | | Magnesii Stearas | | | | Mannitol | 43.6 mg | | | Maydis Amylum | | | | Natrii Laurilsulfas | | | | Pro Compresso Obducto | | |
| |
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 001 | 21 | | | A | | Non | | 002 | 28 | | | A | | Non | | 003 | 35 | 1942.47 | 2128.95 | A | LS | Non |
|
|
